全文获取类型
收费全文 | 52580篇 |
免费 | 3748篇 |
国内免费 | 1135篇 |
专业分类
耳鼻咽喉 | 347篇 |
儿科学 | 959篇 |
妇产科学 | 1493篇 |
基础医学 | 4314篇 |
口腔科学 | 910篇 |
临床医学 | 8347篇 |
内科学 | 7247篇 |
皮肤病学 | 359篇 |
神经病学 | 2089篇 |
特种医学 | 1735篇 |
外国民族医学 | 11篇 |
外科学 | 5106篇 |
综合类 | 7728篇 |
现状与发展 | 1篇 |
预防医学 | 7557篇 |
眼科学 | 326篇 |
药学 | 5080篇 |
102篇 | |
中国医学 | 1819篇 |
肿瘤学 | 1933篇 |
出版年
2023年 | 1026篇 |
2022年 | 2212篇 |
2021年 | 3162篇 |
2020年 | 2439篇 |
2019年 | 2160篇 |
2018年 | 1776篇 |
2017年 | 1859篇 |
2016年 | 1777篇 |
2015年 | 1586篇 |
2014年 | 3256篇 |
2013年 | 3434篇 |
2012年 | 3077篇 |
2011年 | 3256篇 |
2010年 | 2476篇 |
2009年 | 2271篇 |
2008年 | 2205篇 |
2007年 | 2327篇 |
2006年 | 1868篇 |
2005年 | 1691篇 |
2004年 | 1426篇 |
2003年 | 1214篇 |
2002年 | 1114篇 |
2001年 | 974篇 |
2000年 | 819篇 |
1999年 | 778篇 |
1998年 | 628篇 |
1997年 | 626篇 |
1996年 | 570篇 |
1995年 | 510篇 |
1994年 | 505篇 |
1993年 | 377篇 |
1992年 | 405篇 |
1991年 | 376篇 |
1990年 | 326篇 |
1989年 | 316篇 |
1988年 | 263篇 |
1987年 | 215篇 |
1986年 | 198篇 |
1985年 | 260篇 |
1984年 | 225篇 |
1983年 | 147篇 |
1982年 | 187篇 |
1981年 | 168篇 |
1980年 | 148篇 |
1979年 | 135篇 |
1978年 | 106篇 |
1977年 | 93篇 |
1976年 | 87篇 |
1975年 | 93篇 |
1974年 | 63篇 |
排序方式: 共有10000条查询结果,搜索用时 859 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
3.
4.
5.
6.
7.
8.
9.
《Vaccine》2022,40(44):6431-6444
This is a Brighton Collaboration case definition of thrombosis and thromboembolism to be used in the evaluation of adverse events following immunization, and for epidemiologic studies for the assessment of background incidence or hypothesis testing. The case definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of SARS-CoV-2 vaccines. The case definition format of the Brighton Collaboration was followed to develop a consensus definition and defined levels of certainty, after an exhaustive review of the literature and expert consultation. The document underwent peer review by the Brighton Collaboration Network and by selected expert reviewers prior to submission. 相似文献
10.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献